The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
The grants are expected to be received over the next three years, commencing March 2022
These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study
According to Fortune Business Insights, the launch of new PCR-based detection techniques will lead to a surge in demand for PCR instruments in the coming years
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
Moderna's vaccine has already received regulatory approval for adults and adolescents in Australia
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
Subscribe To Our Newsletter & Stay Updated
